Bristol-Myers Wants $1.5B From Gilead After Cancer IP Trial
A Bristol-Myers Squibb subsidiary and Memorial Sloan Kettering Cancer Center have asked a California federal judge to more than double a jury's $752 million patent infringement verdict against a Gilead unit for its...To view the full article, register now.
Already a subscriber? Click here to view full article